Signal regulatory protein is associated with tumor-polarized macrophages phenotype switch and plays a pivotal role in tumor progression
Signal regulatory protein is associated with tumor-polarized macrophages phenotype switch and plays a pivotal role in tumor progression
复制标题
DOI:
10.1002/hep.26391
复制
发表时间:
2013-08-01
期刊:
影响因子:
13.5
通讯作者:
Wang, Hong-yang
中科院分区:
文献类型:
--
作者:
Pan, Yu-fei;Tan, Ye-xiong;Wang, Hong-yang
Macrophages (M) are the major component of infiltrating leukocytes in tumors and exhibit distinct phenotypes according to the microenvironment. We have recently found that signal regulatory protein (SIRP), the inhibitory molecule expressed on myeloid cells, plays a critical role in controlling innate immune activation. Here, we identify that SIRP is down-regulated on monocytes/M isolated from peritumoral areas of hepatocellular carcinoma (HCC) samples, while its level is moderately recovered in intratumor M. In vitro assays demonstrate that SIRP expression is significantly reduced on M when cocultured with hepatoma cells. This reduction is partly due to the soluble factors in the tumor microenvironment. Knockdown (KD) of SIRP prolongs activation of nuclear factor kappa B (NF-B) and PI3K-Akt pathways as M encounter tumor cells, leading to an increased capacity of M for migration, survival, and proinflammatory cytokine production. Enhanced Stat3 and impaired Stat1 phosphorylation are also observed in tumor-exposed SIRP-KD M. Adoptive transfer with SIRP-KD M accelerates mouse hepatoma cells growth in vivo by remolding the inflammatory microenvironment and promoting angiogenesis. SIRP accomplishes this partly through its sequestration of the signal transducer Src homology 2-containing phosphotyrosine phosphatase (SHP2) from IB kinase (IKK) and PI3K regulatory subunit p85 (PI3Kp85). Conclusion: These findings suggest that SIRP functions as an important modulator of tumor-polarized M in hepatoma, and the reduction of SIRP is a novel strategy used by tumor cells to benefit their behavior. Therefore, SIRP could be utilized as a potential target for HCC therapy. (Hepatology 2013;58:680-691)